Francois Gueyffier
Overview
Explore the profile of Francois Gueyffier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
2395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gougeon A, Granal M, Granal M, Massy E, Massy E, Gueyffier F, et al.
Joint Bone Spine
. 2025 Feb;
:105871.
PMID: 40015362
Objectives: Bisphosphonates are widely used to treat osteoporosis, bone cancer, Paget's disease, and hypercalcemia to reduce fracture risk. Observational studies have highlighted rare but serious adverse events (AE). Some meta-analyses...
2.
Hure J, Foucault L, Ghayad L, Marie C, Vachoud N, Baudouin L, et al.
Nat Commun
. 2025 Jan;
16(1):538.
PMID: 39788999
No abstract available.
3.
Hure J, Foucault L, Ghayad L, Marie C, Vachoud N, Baudouin L, et al.
Nat Commun
. 2024 Nov;
15(1):9837.
PMID: 39537633
Oligodendrocytes are critical for CNS myelin formation and are involved in preterm-birth brain injury (PBI) and multiple sclerosis (MS), both of which lack effective treatments. We present a pharmacogenomic approach...
4.
Esparragosa Vazquez I, Sanson M, Chinot O, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, et al.
Neurooncol Adv
. 2024 Jun;
6(1):vdae078.
PMID: 38855053
Background: Based on preclinical studies showing that IDH-mutant (IDHm) gliomas could be vulnerable to PARP inhibition we launched a multicenter phase 2 study to test the efficacy of olaparib monotherapy...
5.
Bouvier F, Chaimani A, Peyrot E, Gueyffier F, Grenet G, Porcher R
BMC Med Res Methodol
. 2024 Mar;
24(1):74.
PMID: 38528447
Background: One key aspect of personalized medicine is to identify individuals who benefit from an intervention. Some approaches have been developed to estimate individualized treatment effects (ITE) with a single...
6.
Seron C, Olivero P, Flores N, Cruzat B, Ahumada F, Gueyffier F, et al.
Front Public Health
. 2024 Jan;
11:1270557.
PMID: 38192555
Type 2 diabetes and its associated cardiovascular risk is an escalating epidemic that represents a significant public health burden due to increased morbidity and mortality, disproportionately affecting disadvantaged communities. Poor...
7.
Vacheron C, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F, et al.
J Crit Care
. 2023 Jun;
78:154330.
PMID: 37267804
Purpose: Septic shock is associated in some patients with a profound immunosuppression. We hypothesized that GM-CSF would reduce the occurrence of ICU-acquired infections in immunosuppressed septic patients. Methods: Randomized double-blind...
8.
Fall M, Grenet G, Le H, Kassai B, Lega J, Boussageon R, et al.
Therapie
. 2023 Feb;
78(6):667-678.
PMID: 36841655
Background: The polypill strategy could become widely accepted in cardiovascular prevention due to reduced costs and its simplicity, which promote compliance. Aspirin is often included as a component of the...
9.
Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, et al.
BMJ Evid Based Med
. 2023 Feb;
29(1):1-5.
PMID: 36788020
No abstract available.
10.
Meunier P, Raynaud C, Guimaraes E, Gueyffier F, Letrilliart L
Ann Fam Med
. 2023 Jan;
21(1):57-69.
PMID: 36690490
Purpose: To identify and quantify the barriers and facilitators to the use of clinical decision support systems (CDSSs) by primary care professionals (PCPs). Methods: A mixed-methods systematic review was conducted...